{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:01:59Z","timestamp":1761742919791},"reference-count":8,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":8327,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[1983,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serum prostate\u2010specific antigen (PA), a new tumor marker of prostate cancer, was evaluated with an enzyme immunoassay (EIA) in various urologic cancer patients and benign prostatic diseases in Japanese. Sera of prostate cancer patients before treatment (n = 27) revealed a range of PA concentrations from 0.12\u201023 ng\/ml with a mean (\u00b1 SD) of 5.78 \u00b1 6.85 ng\/ml, while that of patients with benign prostatic hypertrophy (BPH) (n = 27) showed from less than 0.10 to 2.6 ng\/ml with 0.84 \u00b1 0.81 ng\/ml (mean \u00b1 SD). The mean serum PA levels in nonprostatic cancers were calculated as follows: bladder cancer (n = 21), 0.77 \u00b1 0.55 ng\/ml; renal pelvis or ureteral cancer (n = 6), 0.46 \u00b1 0.47 ng\/ml; renal adenocarcinoma (n = 6), 1.07 \u00b1 0.77 ng\/ml; other urologic cancers (n = 6), 0.55 \u00b1 0.52 ng\/ml. Serum PA ranged from less than 0.10 to 1.1 ng\/ml in patients with prostatitis (n = 5). A significant statistical difference in serum PA levels between prostate cancer and other groups was recognized. These results suggested that an elevation of serum PA value was highly specific to prostate cancer in urological malignancies. The evaluation of serum PA may be of great value in the detection of prostate cancer.<\/jats:p>","DOI":"10.1002\/jso.2930240219","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T08:28:02Z","timestamp":1171960082000},"page":"157-160","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of serum prostate\u2010specific antigen in urologic cancers"],"prefix":"10.1002","volume":"24","author":[{"given":"Toshimi","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Fujihiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneo","family":"Nishiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"159","article-title":"Purification of a human prostate\u2010specific antigen","volume":"17","author":"Wang MC","year":"1979","journal-title":"Invest Urol"},{"key":"e_1_2_1_3_2","first-page":"99","article-title":"Multiple marker evaluation in human prostate cancer with the use of tissue\u2010specific antigens","volume":"68","author":"Kuriyama M","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_4_2","first-page":"4658","article-title":"Quantitation of prostate\u2010specific antigen in serum by a sensitive enzyme immunoassay","volume":"40","author":"Kuriyama M","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/22.12.1084"},{"key":"e_1_2_1_6_2","first-page":"2871","article-title":"A solid\u2010phase fluorescent immunoassay for human prostatic acid phosphatase","volume":"38","author":"Lee CL","year":"1978","journal-title":"Cancer Res"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810901)48:5<1229::AID-CNCR2820480529>3.0.CO;2-L"},{"key":"e_1_2_1_8_2","first-page":"2428","article-title":"A prostate antigen in sera of prostatic cancer patients","volume":"40","author":"Papsidero LD","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_1_9_2","first-page":"319","article-title":"Immunochemical detection of serum prostatic acid phosphatase. Methodology and clinical evaluation","volume":"15","author":"Chu TM","year":"1978","journal-title":"Invest Urol"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.2930240219","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.2930240219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:39:18Z","timestamp":1697805558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.2930240219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,10]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1983,10]]}},"alternative-id":["10.1002\/jso.2930240219"],"URL":"https:\/\/doi.org\/10.1002\/jso.2930240219","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,10]]}}}